An important message from NCRVA regarding coronavirus (COVID-19).

COVID-19 & Your Appointment
Northern California Retina Vitreous Associates logo for print
  • Daly City: 650-994-2100
  • San Mateo: 650-340-0111
  • Mountain View: 650-963-3460
  • Monterey: 831-373-6280
  • East San Jose: 408-251-3500
  • West San Jose: 408-356-8818
Reset Text size:
Reset Text size:

Clinical Trials

Diabetic Retinopathy

Active Studies

ALTITUDE (RegenxBio)

A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants with Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME).


Completed Studies

Cystoid Macular Edema after Cataract Surgery (Allergan)

Phase 2 Study of the Dexamethasone Intravitreal Implant (Ozurdex) for combined Pseudophakic Cystoid Edema and Diabetic Macular Edema after cataract surgery.

DA VINCI (Regeneron)

Phase 2 study of the safety, tolerability and biological effect of repeated aflibercept (Eylea) in diabetic macular edema.

DEGAS (Pfizer)

Phase 2 study of the efficacy and safety of PF-04523655 versus laser in diabetic macular edema.

PACIFIC (Allegro)

A 6 month, phase 2, randomized, double-masked, placebo-controlled multicenter clinical trial designed to evaluate the safety and efficacy of Luminate in inducing PVD in subjects with non-proliferative diabetic retinopathy.

PANORAMA (Regeneron)

A 2 year, Phase 3, multicenter, randomized study of the efficacy and safety of intravitreal aflibercept (Eylea) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy.

RIDE (Genentech)

Phase 3 study of the efficacy and safety of Ranibizumab (Lucentis) in diabetic macular edema.

VISTA (Regeneron)

A 3 year Phase 3 study of the efficacy, safety and tolerability of aflibercept (Eylea) in patients with diabetic macular edema.